You are here: Industry Insights > Market News > NeuroVive and Yungjin Pharm start clinical development

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

98% Bifida Ferment Lysate

rhSOD (cosmetic grade)

Recombinant humanized collagen

Recombinant Humanized Small-molecule Collagen

Recombinant Humanized Small-molecule Collagen Solution

rhSOD

NeuroVive and Yungjin Pharm start clinical development

pharmaasiaJuly 13, 2017

Tag: Yungjin Pharm , NeuroVive , china

Favorites

NeuroVive Pharmaceutical AB and Yungjin Pharm Corporation Ltd (South Korea Stock Market, KRX 003520) announced that the clinical phase I study of KL1333 has started in Korea and that the first healthy volunteer has been enrolled.

The study is a double-blind, placebo-controlled, single-dose, dose-escalation phase I clinical study to investigate the pharmacokinetics and safety/tolerability of KL1333 in healthy subjects. The study is planned to encompass a total of 60 healthy volunteers and will be fully performed by Yungjin Pharm. KL1333 is in development for the treatment of genetic mitochondrial diseases, such as MELAS and Kearns-Sayre syndrome, for which there are no current medicines.

Previous:Piramal to expand pharma presence in US, Europe and Japan

Next:Abzena and OBI Pharma sign licence deal for ThioBridge technology

Pharus Diagnostics LLC Announces Validation of a Laboratory-Developed Test for Early Pancreatic Cancer Detection

PRNewswireDecember 19, 2024

Pharus Diagnostics LLC. (PharusDx), announced a significant step forward in the fight against pancreatic cancer. The company is announcing availability of its OncoSweep™ Pancreas Spotlight

Prenetics' IM8 Announces Collaboration with Mayo Clinic to Develop New Line of Premium Supplements

PRNewswireDecember 19, 2024

PeproMene Bio, Inc. and the Institute for Follicular Lymphoma Innovation Announce $11M Investment to Advance PMB-CT01 (BAFF-R CAR T cell therapy) for Relapsed/Refractory Follicular Lymphoma

PRNewswireDecember 19, 2024

NeuroVive and Yungjin Pharm start clinical development | Pharmasources.com

Innovent Receives Approval of DOVBLERON® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration

PRNewswireDecember 20, 2024

Innovent Biologics announced that China's National Medical Products Administration (NMPA) has approved a New Drug Application (NDA) of DOVBLERON ® .

You may like
More>>

Best castor oil with competitive price from China by manufactuer for export

China factory supply Food Additive Zinc lactate cas 16039-53-5 with free Samples in stock

Chloramphenicol bp ep China for api

Levobetaxolol 98.5%min Pharmaceutical API Eye drops made in china

Zeaxanthin 5% supplier Plant extract made in china

Simvastatin ammonium salt ≥98.0% API Simvastatin Intermediate made in china

China factory direct supply Favorable Price Nicotinic acid with cas 59-67-6

Helicid 98%,USP30 Plant extract Pharmaceutical made in china

Gibberellic acid supplier Pharmaceutical API Plant growth hormone Food additives made in china

China Nature Levodopa L Dopa Price 59-92-7 L-dopa Powder Mucuna Pruriens Extract

NeuroVive and Yungjin Pharm start clinical development

Related News

Pharus Diagnostics LLC Announces Validation of a Laboratory-Developed Test for Early Pancreatic Cancer Detection

Prenetics' IM8 Announces Collaboration with Mayo Clinic to Develop New Line of Premium Supplements

PeproMene Bio, Inc. and the Institute for Follicular Lymphoma Innovation Announce $11M Investment to Advance PMB-CT01 (BAFF-R CAR T cell therapy) for Relapsed/Refractory Follicular Lymphoma

Innovent Receives Approval of DOVBLERON® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration

You may likeMore>>

You may like
More>>